Piper Sandler raises Oscar Health stock price target on ACA growth

Piper Sandler maintained an Overweight rating on Oscar Health and set a $48 price target, implying nearly 50% upside from the $32.34 share price, based on a 12x multiple of 2030 adjusted EPS. Oscar's Q2 2026 adjusted EPS of $1.10 beat the $0.37 consensus estimate, while $4.88B in revenue exceeded the $4.73B forecast. The company also raised 2026 operating-income guidance by $100M to $600M-$800M, supported by a 50bp improvement in its medical loss ratio and anticipated ACA enrollment growth from 2027 onward.

Analysis

The relevant rerating mechanism is not near-term earnings but a sharp reduction in the perceived durability discount on Oscar’s individual-market model. That makes OSCR unusually exposed to any evidence that unit economics are repeatable through the next pricing cycle: medical-cost trend, retention, risk-adjustment transfers, and administrative-cost leverage matter more than another single-quarter beat. Conversely, the valuation framework being anchored to far-dated earnings creates meaningful duration risk; a modest reduction in assumed enrollment growth or mature-margin potential can compress the multiple before reported fundamentals deteriorate.

Competitive effects are likely asymmetric. If Oscar converts brand awareness and technology-enabled navigation into share gains, the most exposed public incumbents are ACA-heavy managed-care operators such as CNC and MOH, where exchange membership is less differentiated and incremental pricing competition can impair margins. The more immediate catalyst path is 1-3 months: state rate filings, open-enrollment plan design, and 2027 policy clarity should determine whether growth is profitable rather than merely enrollment-driven. Over 6-18 months, the thesis depends on the regulatory treatment of premium subsidies and risk-adjustment economics; adverse policy changes could lower the addressable market while simultaneously worsening the enrolled risk pool.

Consensus may be underestimating operating leverage if membership expansion occurs without renewed customer-acquisition spending, but it is also treating an unusually favorable medical-cost period as structural. The key falsifier is not headline revenue: it is a reversal in the medical-loss-ratio trajectory, rising PMPM administrative expense, or rate filings that imply inadequate pricing for medical trend. Given the prior share-price move and wide target dispersion, the risk/reward favors buying confirmation on enrollment and pricing data rather than chasing a broker-driven gap higher.

Key Decisions for Investors

• Maintain OSCR as a tactical watch-to-buy, not a fresh full-size long, until 2027 exchange-rate filings and open-enrollment product data validate profitable share gains; add only if management sustains medical-loss-ratio improvement while reaffirming operating-income conversion. Reassess if MLR deteriorates by more than 100 bps versus plan or if administrative costs rise faster than membership.
• For a 3-6 month relative-value expression, consider long OSCR / short CNC in equal beta-adjusted dollars after a pullback: Oscar has greater upside to successful member acquisition and fixed-cost absorption, while Centene is more exposed to exchange pricing and policy uncertainty. Exit if regulatory developments preserve incumbent economics but reduce Oscar’s differentiated growth runway.
• Avoid unhedged long-dated OSCR calls at current implied enthusiasm; if options liquidity permits, use a 6-9 month call spread funded with an upside call sale rather than paying for an open-ended terminal-value narrative. The trade requires confirmation that implied volatility is below the expected range around enrollment and rate-filing events.
• Monitor MOH, CNC and ELV for negative read-through only after state-level pricing disclosures. Broad managed-care weakness without evidence of exchange-share migration would more likely signal medical-cost inflation, a reason to reduce OSCR exposure rather than add.